Skip to content


Immunadsorption doctor male

Treatment of autoimmune diseases


Not all products and services are cleared or available for sale in all EU countries. Check your country web site for details. 

The product labels depicted may differ due to regulatory adaptations and changes in the legal form of the legal manufacturer.


Antibodies or autoantibodies often play a key role in solid organ transplantation and in autoimmune disorders. This is frequently associated with the activation or agonistic stimulation of cell-surface mechanisms (e.g. complement factors) or with antagonistic blockage of certain receptors. Immunoadsorption therapy removes antibodies or immune complexes from the blood plasma. Due to its selectivity, it can treat a wide range of autoantibody mediated clinical indications.1

During immunoadsorption, the targeted antibody classes are largely removed through strong binding affinity to different ligands of the adsorber matrix. This can alleviate the symptoms of disease, including in the acute state, and possibly prevent the disease’s progression.

Effective broad-spectrum immunoadsorption2,3

A number of serious diseases have an autoimmune pathophysiology and are sometimes difficult to treat, particularly when a quick and efficient elimination of autoantibodies is needed.

The GLOBAFFIN column is intended for the removal of immunoglobulins from the plasma of patients with specific autoantibodies associated with their disease.4

Treatment with GLOBAFFIN is characterized by:

  • Immunoadsorber with synthetic peptide ligand (peptide-GAM146)2
  • Twin adsorber system with multiple-use and multiple-pass characteristics
  • Semi-selective and efficient removal of IgG immunoglobulines5



Medical information

Immunoadsorption in COVID-19
Related content
Lipoprotein apheresis

Removal of lipoproteins from the blood.

Discover our new apheresis concept APRΞD and other platforms from Fresenius Medical Care.

Hamilton P et al. 2019, chapter 4 in Karkar A (ed.), Aspects in Continuous Renal Replacement Therapy. IntechOpen, London

Rönspeck W et al. Ther Apher Dial 2003; 7(1):91-97

Fuchs K et al. Ther Apher Dial 2022; 26:229-241

Instructions for Use GLOBAFFIN, Ref. 35840034/5

Biesenbach P et al. Atheroscler Suppl 2009; 10(5):114-121

Contact Us

Request a sales meet, demo or brochure by using this contact form

The information you provide will only be used to answer your query. For more information on how we process your Personal Data please read our privacy policy

This contact form is not intended to submit an adverse event related to medicinal products. To report an adverse event, please contact us at corporate-drug-safety(at)

Therapeutic Apheresis Product